Skip to Content

Zolinza Approval History

  • FDA approved: Yes (First approved October 6th, 2006)
  • Brand name: Zolinza
  • Generic name: vorinostat
  • Dosage form: Capsules
  • Company: Merck & Co., Inc.
  • Treatment for: Cutaneous T-cell Lymphoma

Zolinza (vorinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies.

Development History and FDA Approval Process for Zolinza

Oct  6, 2006Approval Zolinza Merck & Co., Inc. - Treatment for Cutaneous T-cell Lymphoma
Jun  7, 2006Zolinza, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), to Receive Priority Review from U.S. Food and Drug Administration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.